Journal of Scientific Dentistry

Register      Login

VOLUME 11 , ISSUE 1 ( January-June, 2021 ) > List of Articles

REVIEW ARTICLE

A Review on COVID-19 Outbreak: An Unprecedented Threat to the Globe

Yamini Kanipakam, Vezhavendhan Nagaraja, Bala Maddileti Gandla, Santha Devy Arumugam

Keywords : Coronavirus, Epidemic, Global health emergency, Pandemic

Citation Information : Kanipakam Y, Nagaraja V, Gandla BM, Arumugam SD. A Review on COVID-19 Outbreak: An Unprecedented Threat to the Globe. 2021; 11 (1):37-41.

DOI: 10.5005/jp-journals-10083-0942

License: CC BY-NC 4.0

Published Online: 01-07-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

The coronavirus outbreak in December 2019 has added renewed interest in bygone micro enemy and upraise questions about the ability of current protective measures in our healthcare system to handle this threat. It is a known fact that coronaviruses to cause respiratory infections in humans for over six decades, but their pandemic potentiality has been addressing for the last few years. Coronavirus disease-19 (COVID-19) has caused so much concern around the world that the World Health Organization (WHO) on January 30, 2020, proclaimed it as a world health emergency, and on March 11, 2020, the WHO declared COVID-19 a global-wide pandemic. The ease at which this virus spread caused people to use some precautionary measures such as masks and gloves, resulting in the generation of a large amount of medical waste in the environment. To reduce the spread of the virus, human beings were put on restricted at homes in the name of lockdown. This pandemic has also altered people\'s lifestyles. This analysis reflects the current state of public health impact; we deal with current information on coronaviruses, including epidemiology, signs and symptoms, disease manifestation, and treatment and prevention strategies.


  1. Assessment RR, Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK–ninth update.
  2. Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, et al. A new threat from an old enemy: re-emergence of coronavirus. Int J Mole Med 2020;45(6):1631–1643. DOI: 10.3892/ijmm.2020.4555.
  3. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respirat Med 2020;8(4):420–422. DOI: 10.1016/S2213-2600(20)30076-X.
  4. Saadat S, Rawtani D, Hussain CM. Environmental perspective of COVID-19. Sci Total Environ 2020. 138870. DOI: 10.1016/j.scitotenv.2020.138870.
  5. Vannabouathong C, Devji T, Ekhtiari S, Chang Y, Phillips SA, Zhu M, et al. Novel coronavirus COVID-19: current evidence and evolving strategies. J Bone Joint Surg Am Vol 2020;102(9):734. DOI: 10.2106/JBJS.20.00396.
  6. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708–1720. DOI: 10.1056/NEJMoa2002032.
  7. World Health Organization (WHO), Coronavirus disease 2019 (COVID-19) situation report – 51.2020.
  8. Mao R, Liang J, Shen J, Ghosh S, Zhu LR, Yang H. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol 2020;5(5):425–427. DOI: 10.1016/S2468-1253(20)30076-5.
  9. Tsai J, Wilson M. COVID-19: a potential public health problem for homeless populations. Lancet Public Health 2020;5(4):e186–e187. DOI: 10.1016/S2468-2667(20)30053-0.
  10. Kooraki S, Hosseiny M, Myers L, Gholamrezanezhad A. Coronavirus (COVID-19) outbreak: what the department of radiology should know. J Am Coll Radiol 2020;17(4):447–451. DOI: 10.1016/j.jacr.2020. 02.008.
  11. Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis 2020;20(5):553–558. DOI: 10.1016/S1473-3099(20)30144-4.
  12. Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus disease (COVID-19): spectrum of CT findings and temporal progression of the disease. Acade Radiol 2020;27(5):603–608. DOI: 10.1016/j.acra.2020.03.003.
  13. Richman DD, Whitley RJ, Hayden FG, ed. Clinical virology. John Wiley & Sons; 2016.
  14. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565–574. DOI: 10.1016/S0140-6736(20)30251-8.
  15. Ather A, Patel B, Ruparel NB, Diogenes A, Hargreaves KM. Coronavirus disease 19 (COVID-19): implications for clinical dental care. J Endod 2020;46(5):584–595. DOI: 10.1016/j.joen.2020.03.008.
  16. World Health Organization, Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003.
  17. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015;386(9997):995–1007. DOI: 10.1016/S0140-6736(15)60454-8.
  18. https://covid19.who.int/?gclid.
  19. Movert E, Wu Y, Lambeau G, Kahn F, Touqui L, Areschoug T. Using patient pathways to accelerate the drive to ending tuberculosis. J Infect Dis 2013;208(12):2025–2035. DOI: 10.1093/infdis/jit359.
  20. Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology 2003;8(Suppl 1):S9–S14.
  21. Xu RH, He JF, Evans MR, Peng GW, Field HE, Yu DW, et al. Epidemiologic clues to SARS origin in China. Emerg Infect Dis 2004;10(6):1030. DOI: 10.3201/eid1006.030852.
  22. Mobaraki K, Ahmadzadeh J. Current epidemiological status of Middle East respiratory syndrome coronavirus in the world from 1.1.2017 to 17.1.2018: a cross-sectional study. BMC Infect Dis 2019;19(1):351. DOI: 10.1186/s12879-019-3987-2.
  23. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–513. DOI: 10.1016/S0140-6736(20)30211-7.
  24. Lv L, Li G, Chen J, Liang X, Li Y. Comparative genomic analysis revealed specific mutation pattern between human coronavirus SARS-CoV-2 and Bat-SARSr-CoV RaTG13. BioRxiv 2020. DOI: 10.1101/2020.03.15.993097.
  25. Fan Y, Zhao K, Shi ZL, Zhou P. Bat coronaviruses in China. Viruses 2019;11(3):210. DOI: 10.3390/v11030210.
  26. Kelly H, Peck HA, Laurie KL, Wu P, Nishiura H, Cowling BJ. The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccination. PLoS ONE 2011;6(8). DOI: 10.1371/journal.pone.0021828.
  27. World Health Organization (WHO). Novel coronavirus (2019-nCoV) situation report-1.2020.
  28. World Health Organization (WHO). Novel coronavirus (2019-nCoV) situation report-2.2020.
  29. World Health Organization (WHO). Coronavirus disease 2019 (COVID-19) situation report – 56.2020.
  30. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200316-sitrep-56-covid19.pdf?sfvrsn=9fda7db2_6.
  31. World Health Organization. Novel coronavirus—china. 2020.
  32. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Eng J Med 2020;382(10):929–936. DOI: 10.1056/NEJMoa2001191.
  33. Chen P, Mao L, Nassis GP, Harmer P, Ainsworth BE, Li F. Wuhan coronavirus (2019-nCoV): the need to maintain regular physical activity while taking precautions. J Sport Health Sci 2020;9(2):103. DOI: 10.1016/j.jshs.2020.02.001.
  34. World Health Organization. IHR procedures concerning public health emergencies of international concern (PHEIC). Geneva: World Health Organization.
  35. World Health Organization (WHO). Novel coronavirus (2019-nCoV) situation report – 21. 2020.
  36. World Health Organization (WHO). Rolling updates on coronavirus disease (COVID-19). 2020.
  37. World Health Organization (WHO). Coronavirus disease 2019 (COVID-19) situation report – 50. 2020.
  38. World Health Organization (WHO). WHO Director-General's opening remarks at the media briefing on COVID-19. 2020.
  39. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2—Singapore, January 23–March 16, 2020. Morbid Mortal Weekly Rep 2020;69(14):411. DOI: 10.15585/mmwr.mm6914e1.
  40. Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Eng J Med 2020;382(16):1564–1567. DOI: 10.1056/NEJMc2004973.
  41. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect 2020;104(3):246–251. DOI: 10.1016/j.jhin.2020.01.022.
  42. Centers for Disease Control and Prevention. Coronavirus disease 2019: how it spreads. 2020.
  43. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020;382(10):970–971. DOI: 10.1056/NEJMc2001468.
  44. Riccardo F, Ajelli M, Andrianou X, Bella A, Del Manso M, Fabiani M, et al. Epidemiological characteristics of COVID-19 cases in Italy and estimates of the reproductive numbers one month into the epidemic. medRxiv 2020;25(49):2000790. DOI: 10.2807/1560-7917.ES.2020.25.49.2000790.
  45. An der Heiden M, Hamouda O. Schätzung der aktuellen Entwicklung der SARS-CoV-2-Epidemie in Deutschland–nowcasting. Epid Bull 2020;17:10–15.
  46. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020(7809):1–5. DOI: 10.1038/s41586-020-2196-x.
  47. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020;20(6):656–657. DOI: 10.1016/S1473-3099(20)30232-2.
  48. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of COVID-19 outbreak in the municipality of Vo, Italy. medRxiv 2020.
  49. Peng L, Liu J, Xu W, Luo Q, Deng K, Lin B, et al. 2019 Novel coronavirus can be detected in urine, blood, anal swabs and oropharyngeal swabs samples. medRxiv 2020.
  50. Colavita F, Lapa D, Carletti F, Lalle E, Bordi L, Marsella P, et al. SARS-CoV-2 isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection. Ann Int Med 2020(3):M20–1176. DOI: 10.7326/M20-1176.
  51. Aguilar JB, Faust JS, Westafer LM, Gutierrez JB. Investigating the impact of asymptomatic carriers on COVID-19 transmission. medRxiv 2020.
  52. Corman VM, Rabenau HF, Adams O, Oberle D, Funk MB, Keller-Stanislawski B, et al. SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission. Transfusion 2020;60(6):1119–1122. DOI: 10.1111/trf.15841.
  53. Chow EJ, Schwartz NG, Tobolowsky FA, Zacks RL, Huntington-Frazier M, Reddy SC, et al. Symptom screening at illness onset of health care personnel with SARS-CoV-2 infection in King County, Washington. JAMA 2020;323(20):2087–2089. DOI: 10.1001/jama.2020.6637.
  54. Centers for Disease Control and Prevention. Symptoms of coronavirus. Retrieved from. 2020.
  55. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020;18(6):1421–1424. DOI: 10.1111/jth.14830.
  56. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemos 2020;18(4):844–847. DOI: 10.1111/jth.14768.
  57. Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemos 2020;120(05):876–878. DOI: 10.1055/s-0040-1709650.
  58. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061–1069. DOI: 10.1001/jama.2020.1585.
  59. FIND. SARS-COV-2 diagnostic pipeline. 2020 (https://www.finddx.org/covid-19/pipeline/).
  60. Babiker A, Myers CW, Hill CE, Guarner J. SARS-CoV-2 testing: trials and tribulations. Am J Clin Pathol 2020;153(6):706–708. DOI: 10.1093/ajcp/aqaa052.
  61. Han H, Luo Q, Mo F, Long L, Zheng W. SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients. Lancet Infect Dis 2020;20(6):655–656. DOI: 10.1016/S1473-3099(20)30174-2.
  62. Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. MedRxiv 2020.
  63. Centers for Disease Control. Pevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19).
  64. Food and Drug Administration. FAQs on diagnostic testing for SARS-CoV-2. 2020.
  65. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20) 30183-5.
  66. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Int Med 2020;180(7):934–943. DOI: 10.1001/jamainternmed.2020.0994.
  67. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020;323(13):1239–1242. DOI: 10.1001/jama.2020.2648.
  68. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.
  69. Centers for Disease Control and Prevention. Interim guidance for implementing home care of people not requiring hospitalization for coronavirus disease 2019 (COVID-19). 2020.
  70. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6(1):1–4. DOI: 10.1038/s41421-019-0132-8.
  71. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269–271. DOI: 10.1038/s41422-020-0282-0.
  72. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Translat Med 2017;9(396):eaal3653. DOI: 10.1126/scitranslmed.aal3653.
  73. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11(1):1–4. DOI: 10.1038/s41467-019-13940-6.
  74. De Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceed Nat Acad Sci 2020;117(12):6771–6776. DOI: 10.1073/pnas.1922083117.
  75. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 2020. 104362. DOI: 10.1016/j.jcv.2020. 104362.
  76. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respirat Med 2020;8(4):e21. DOI: 10.1016/S2213-2600(20)30116-8.
  77. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17(5):259–260. DOI: 10.1038/s41569-020-0360-5.
  78. World Health Organization, Coronavirus disease (COVID-19) technical guidance: infection prevention and control. 2020.
  79. Public Health England. COVID-19: infection prevention and control (IPC). 2020.
  80. Government of Canada. Personal protective equipment against COVID-19. 2020.
  81. Australian Government Department of Health. Interim recommendations for the use of personal protective equipment (PPE) during hospital care of people with Coronavirus Disease 2019 (COVID-19). 2020.
  82. Centers for Disease Control and Prevention. Who needs PPE. 2020 (https://www.cdc.gov/coronavirus/2019-ncov/hcp/using-ppe.html).
  83. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020.; 25(10):2000180. DOI: 10.2807/1560-7917.ES.2020.25.10.2000180.
  84. Zhang J, Tian S, Lou J, Chen Y. Familial cluster of COVID-19 infection from an asymptomatic. Crit Care 2020;24(1):1–3. DOI: 10.1186/s13054-020-2817-7.
  85. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323(14):1406–1407. DOI: 10.1001/jama.2020.2565.
  86. Klompas M, Morris CA, Sinclair J, Pearson M, Shenoy ES. Universal masking in hospitals in the Covid-19 era. N Engl J Med 2020;383(2):e9. DOI: 10.1056/NEJMc2020836.
  87. CHAPTER I. The Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002. Issues Med Ethics 2002;10:3.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.